KDR and hypertensive disorder: VEGFR-2 inhibition abrogates NO synthesis, VEGFR-1+2 inhibition reduces PGI2 synthesis and VEGFR-(1+2+3) inhibition promotes vessel rarefaction, all of which are mechanisms involved in hypertension development [41].